Last reviewed · How we verify

NCT04630886

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

Terminated EARLY_PHASE1 Last updated 19 November 2024
What this trial tests

EARLY_PHASE1 trial testing Tranexamic acid injection in Skin Neoplasms in 34 participants. Terminated before completion.

Timeline
16 June 2021
Primary endpoint
16 January 2024
16 January 2024

Quick facts

Lead sponsorRiley McLean
PhaseEARLY_PHASE1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment34
Start date16 June 2021
Primary completion16 January 2024
Estimated completion16 January 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Riley McLean

Who can join

Adults 18 to 99, any sex, with Skin Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the use of locally injected tranexamic acid (TXA) under the skin during Mohs micrographic surgery for removal of skin cancers in patients on anticoagulation. TXA may be helpful in reducing bleeding and pain during surgery, and may also lead to fewer post-operative complications following surgery such as graft loss, specifically in patients on blood-thinners.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Efficacy and Safety of Tranexamic Acid in Cancer Surgery. An Update of Clinical Findings and Ongoing Research.
    Zec T, Di Napoli R, Fievez L, Ben Aziz M, et al · · 2022 · cited 6× · PMID 35818514 · DOI 10.2147/jmdh.s337250

Verify or expand the search:

Other trials of Tranexamic acid injection

Trials testing the same drug.

Other recruiting trials for Skin Neoplasms

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing